| Market Capitalization (Millions $) |
55 |
| Shares
Outstanding (Millions) |
84 |
| Employees |
120 |
| Revenues (TTM) (Millions $) |
138 |
| Net Income (TTM) (Millions $) |
32 |
| Cash Flow (TTM) (Millions $) |
21 |
| Capital Exp. (TTM) (Millions $) |
0 |
Cytomx Therapeutics Inc
CytomX Therapeutics Inc. is a clinical-stage biopharmaceutical company that is primarily engaged in the discovery and development of novel, breakthrough cancer immunotherapies, including a class of heterogeneous immunotherapies known as Probody therapeutics.
The company was founded in 2008 and is headquartered in South San Francisco, California. CytomX Therapeutics was built on scientific innovation from the lab of Dr. James A. Wells at University California, San Francisco, which has led to the development of the proprietary Probody platform technology.
The Probody platform technology encompasses a unique and differentiated approach to cancer immunotherapy based on the selective, tunable, and conditional targeting of cancer cells. The Probody therapeutics are designed to remain inactive in normal tissues but activated in the tumor microenvironment. This approach allows for a more targeted attack on the cancer cells and minimizes damage to healthy tissue.
The company's lead Probody therapeutic asset is CX-072, which is a fully human anti-PD-L1 Probody therapeutic that is currently in phase 1/2 clinical trials for the treatment of solid tumors. The company also has several other Probody therapeutics in preclinical development, including those targeting the CTLA-4, CD166, and PD-1 pathways, as well as the T-cell redirecting bispecific antibodies.
CytomX Therapeutics also has collaborations with several leading pharmaceutical companies, including Amgen, Bristol-Myers Squibb, and Pfizer, to discover and develop Probody therapeutics against certain oncology targets.
In addition to its Probody platform technology, CytomX Therapeutics also has a proprietary antibody discovery platform known as Probodies Xtend. The Probodies platform is designed to improve the pharmacokinetic properties of monoclonal antibodies by reducing their clearance rate and extending their half-life, which should improve their efficacy for cancer immunotherapy.
Overall, CytomX Therapeutics Inc. is a highly innovative clinical-stage biopharmaceutical company at the forefront of cancer immunotherapy research, with a differentiated and proprietary platform technology that has significant translational and commercial potential.
Company Address: 151 Oyster Point Boulevard, South San Francisco 94080 CA
Company Phone Number: 515-3185 Stock Exchange / Ticker: NASDAQ CTMX
|
3.03% 